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Chapter 1
Introduction

1.1 Cancer
Cancer is a type of disease defined by abnormal growth of cells called tumor resulting from
the accumulation of gene mutations with two heritable properties; uncontrolled proliferation and
colonization into other tissues. Tumors can be classified as benign or malignant. Benign tumors
grow locally and remain clustered together, thus considered noncancerous, while malignant
tumors have the ability of invading neighboring tissues, entering blood vessels and lymph system
and metastasize to different sites. The progression of cancer can be explained by three key steps
involving (a) initiation, in which normal cell is converted into initiated or abnormal cell, (b)
promotion, the process of which the initiated cells is transformed into a pre-malignant cells, and
(c) progression, by which the cells become neoplastic or malignant [1].
1.2 Pancreatic Cancer
Pancreatic cancer is a condition in which malignant cells are found in pancreatic tissues.
The pancreas is a 6-inch organ located behind the stomach made up of both exocrine and
endocrine glands. The exocrine cells of the pancreas secrete digestive enzymes which are being
released into a system of small ducts that lead to the main pancreatic duct. In the digestive
system, both pancreatic duct and bile duct connect together where pancreatic juice and bile will
be emptied into the duodenum, aiding in the digestion of fats, proteins and carbohydrates. On the
other hand, the endocrine cells of the pancreas are involved in the production of hormones,
mainly insulin and glucagon. These hormones are secreted by islet cells into the bloodstream,
working together in maintaining the normal level of blood glucose in the body.
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Pancreatic cancer is currently ranked as the fourth leading cause of cancer-related deaths
in the United States with 95% of the cases emerging from the exocrine cells, the most common
type being the pancreatic ductal adenocarcinoma (PDAC), while the remaining 5% develop
from the endocrine cells [2]. Although accounting for the least percentage of incidences among
other types of digestive system cancers, pancreatic cancer still remains as one of the most lethal
types of malignancies with the five year survival rate of less than five percent. The American
Cancer Society estimated that in 2013, 45220 of new cases of pancreatic cancer would be
diagnosed and 85% of death from this number is expected due to this disease [3]. Late
diagnosis, early metastasis of tumors and poor response to treatments contribute to the high
mortality rate [4].
It is now widely accepted that the cause for pancreatic cancer is related to the
accumulation of genetic mutations and alterations which results in oncogenes being highly
expressed, inactivation of tumor suppressor genes and overexpression of growth factors and their
receptors [5, 6].
In pancreatic cancer, K-ras mutations are the most commonly seen oncogene mutations
which appear in more than 95% of pancreatic cancer tissues. The normal K-ras proto-oncogene
encodes a guanine nucleotide-binding protein which plays role in cell growth and differentiation
[7, 8]. The activated K-ras oncogene by means of point mutations in either codon 12, 13 or 61
has an abnormal increase in membrane-bound ras proteins which appears to induce tumor
development by altering the signal transduction pathway across the membrane leading to an
abnormal, uncontrolled cell growth [8]. It is believed that mutations of K-Ras take place in the
early stage of pancreatic carcinogenesis [6].
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P53 is a tumor suppressor gene located on the short arm of chromosome 17 that encodes
a 53kDa nuclear phosphoprotein which plays role in the negative regulation of cell growth and
proliferation. It is an important tumor suppressor genes inactivated in pancreatic cancer [9]. P53
mutations have been found to occur in 40% to 70% of pancreatic adenocarcinoma cases and its
contribution to tumorigenesis is suggested to be through the inhibition of apoptosis [10]. In
contrast to K-Ras oncogene, whether p53 abnormalities are an early or late event in pancreatic
cancer is inconclusive [6].
Growth factors and their receptors pose meaningful functions in the progression of tumor
[11]. Over expression of growth factors such as EGF, TGF alpha, TGF beta 1-3, growth factor
receptors including EGF receptor, c-erbB-2, c-c-ebB-3, TGF beta receptor I-III together with
genetic mutations mainly K-ras, p53 are of significant existance in a number of gastrointestinal
cancers [12]. These abnormalities stimulate tumor growth and exaggerate the metastatic behavior
of pancreatic cancer cells to such a degree that may contribute to poor prognosis following
treatments of this disease [6]. The mouse model selected for the study has mutations in K-ras and
p53 genes, leading to pancreatic cancer manifestation, similar to human.
1.2.1 Clinical presentation and diagnosis
Symptoms presented by pancreatic cancer are not exclusive to the disease and differ
depending on the location of tumor as well as the stage of the disease. Although the etiology of
pancreatic cancer remains unknown, several risk factors have been suggested such as male
gender, black race, meat and fat consumption, cigarette smoking, pancreatic ductal hyperplasia
and chronic pancreatitis. Since the majority of tumors develop in the head of the pancreas,
obstructive cholestasis is normally manifested. Rarely, a pancreatic tumor may also cause
gastrointestinal bleeding or duodenal obstruction while obstruction of the pancreatic duct by
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tumor may lead to pancreatitis. Pancreatic cancer generally causes abdominal discomfort, nausea
and dull, deep upper abdominal pain. For most patients, systemic manifestations of this disease
include anorexia, weight loss and asthenia. Other less common manifestations include deep and
superficial venous thrombosis, increased abdominal girth, panniculitis, gastric-outlet obstruction
and depression. Upon physical examination, jaundice, temporal wasting, hepatomegaly and
ascites may be observed. Patients may also have mild liver-function test abnormalities,
hyperglycemia and anemia [2, 13, 14].
Commonly, contrast-enhanced computerized tomography (CT) is sufficient to help in the
diagnosis of pancreatic cancer. Other imaging tests use to diagnose this disease include
ultrasound and magnetic resonance imaging (MRI). Some other diagnostic tools that is also
useful are endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography
(ERCP). In terms of serum biomarker, CA 19-9 is the only biomarker that has demonstrated
clinical usefulness for therapeutic monitoring and early detection of recurrent event of pancreatic
cancer despite its limitation of not being a solely specific biomarker for this disease [15, 16]. CA
19-9 may also be elevated in other malignancies such as lung cancer, colorectal cancer and
cancer of the gall bladder as well as in non-cancerous conditions such as gall stones, pancreatitis,
liver disease and cystic fibrosis. In our study, tumor development and progression in live animals
was monitored by MRI.
1.2.2 Pancreatic cancer staging
According to the most recent edition of the American Joint Committee on Cancer,
pancreatic cancer is staged based on tumor-node-metastasis classification. Staging of pancreatic
cancer comprised of five stages namely stage 0, stage I, stage II, stage III and stage IV together
with tumor grade, nodal status and distant metastases. In stage 0, abnormal cells are found in the
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lining of the pancreas. These abnormal cells may become cancer and spread into nearby
normal tissue. Stage 0 is also called carcinoma in situ, an early form of cancer defined by
abnormal cells are still within the site of origin with the absence of spreading or invasion to
nearby tissues. In stage I, cancer has formed and is found in the pancreas only. Based on the size
of the tumor, stage I is divided into stage IA (tumor size of 2 centimeters or smaller) and stage IB
(tumor

size

larger

than

2

centimeters).

In stage

II, cancer may

have

spread

to

nearby tissue and organs, and may have spread to lymph nodes near the pancreas. Stage II is
further divided into stage IIA where cancer has spread to nearby tissue and organs but has not
spread to nearby lymph nodes and stage IIB where cancer has spread to nearby lymph nodes and
may have spread to nearby tissue and organs. As pancreatic cancer advances into stage
III, cancer has now spread to the major blood vessels near the pancreas including the superior
mesenteric artery, celiac axis, common hepatic artery, and portal vein, and may have also spread
to nearby lymph nodes. In the final stage of pancreatic cancer, stage IV, cancer may be of any
size and has metastasize to distant organs, such as the liver, lung, and peritoneal cavity. It may
have also spread to organs and tissues near the pancreas or to lymph nodes [17].
In PDAC, the growth of pancreatic cancer arises from the ductal epithelium and
progresses from pre-malignant lesion to fully invasive cancer [2]. The progression of this disease
can also be graded by looking at the changes that happen to lesion called pancreatic
intraepithelial neoplasia (panIN). PanINs are proliferations of the smaller pancreatic ducts that
can be viewed microscopically. Classification of PanIN represent step by step morphological
alterations that happen in the pancreatic ductal epithelium. A normal pancreatic duct is
characterized by low cuboidal, non-mucinuous cells in a single layer formation. Low-grade
PanINs (PanIN-1a and PanIN-1b) are characterized by the change from a cuboidal duct
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epithelium to elongated cells and by the abundant accumulation of mucin. PanIN-1a lesion is
made up of columnar shape cells with the presence of mucin production. PanIN-1b lesion is
somewhat identical to PanIN-1a except for its architectural difference. PanIN-1b has a papillary,
micropapillary or basally pseudostratified architecture. As the lesions advance from PanIN-1 to
PanIN-2, some nuclear abnormalities have emerged which can be viewed under a microscope.
The architectural make up of mucinuos epithelial lesion of PanIN-2 can either be flat or
papillary. Some of the nuclear alterations that can be seen in PanIN-2 lesion include loss of
polarity, nuclear crowding, enlarged nuclei, pseudo-stratification and hyperchromatism. PanIN-3
lesion is a pre-invasive form of adenocarcinoma (carcinoma in situ). It is architecturally
papillary or micropapillary, however, they may also appeared flat. This lesion may form
budding into the pancreatic lumen with the observance of severe nuclear atypia and some
abnormal mitosis [18]. In the overall study, the PanIN system was used to confirm the presence
of cancer in the pancreas and liver tissue by histological methods.
1.2.3 Treatment and prognosis
Treatment plan for pancreatic cancer depends on the possibility of performing complete
surgery to remove the cancer. Surgery is the only potential treatment to cure the disease.
Unfortunately this option is only limited to patients diagnosed with early stage of pancreatic
cancer, mainly stage I and some of stage II cases [19, 20]. Only 20% of cases can be surgically
removed at the time of diagnosis while in the remaining 80% of cases, the tumor is unresectable
or curative treatment by surgical techniques alone is less beneficial [20]. The most common
operative procedures involve cephalic pancreatoduodenectomy (the Whipple procedure); when
the tumor is in the head or uncinate process, distal subtotal pancreatectomy; when the tumor is
located the body or tail of the pancreas and in some cases may involve total pancreatectomy.
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Observations from several randomized clinical trials demonstrate that a more extensive surgical
resection does not improve survival due to the increase risk of postoperative morbidity [2]. This
poor prognosis is contributed by several factors including large tumor size, high tumor grade,
lymph-node metastases and high level of CA 19-9 that continue to elevate persistently in
postoperative setting [21, 22].
Despite being the only possible curative treatment for pancreatic cancer, prognosis
following total resection of tumor alone in early-stage patients is somewhat disappointing [2].
Data from several studies have shown that adjuvant therapy through postoperative administration
of chemotherapy with either leucovorin

and fluorouracil or gemcitabine improves overall

survival [23-25]. In addition, the combination of gemcitabine with fluorouracil given as
continuous infusion and radiation therapy has also shown an increase in overall survival with a
median survival of 20 to 22 months [2, 26] . Hence, the use of gemcitabine alone or gemcitabine
in combination with fluruouracil-based chemoradiation postoperatively can be acknowledged as
the standard of care for the management of early-stage pancreatic cancer. Interestingly, the
emerging use of preoperative (neoadjuvant) gemcitabine-based chemoradiation treatment has
also been demonstrated to be at least as effective as postoperative (adjuvant) treatment in patients
with resectable pancreatic cancer [27].
As the disease progresses to becoming locally and systemically advanced, tumor is no
longer resectable. In these cases, treatment is palliative with median overall survival ranges from
9 to 10 months. Treatment options diverge from chemotherapy alone to combination of treatment
with chemoradiation therapy and chemotherapy. Data from several randomized trials has
established that chemoradiation therapy is better than radiation therapy alone [28, 29].
Gemcitabine, a genotoxic drug has been the treatment of choice for pancreatic cancer particularly
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for patients with nonresectable pancreatic cancer. It is the current standard therapy that is known
to extend survival by a matter of weeks [30]. Several new agents have been tested in
combination with gemcitabine in clinical trials but with no betterment in outcome [13, 31, 32].
The only agent, used in combination with gemcitabine that has shown a small yet significant
increase in survival among patients diagnosed with advanced pancreatic cancer is erlotinib
though this combination has more toxicity when compared with erlotinib alone [33]. To date, the
treatment approach

in acceptance for patients with advanced pancreatic cancer is either

gemcitabine administration alone or gemcitabine in combination with a platinum agent, erlotinib,
or a fluropyrimidine [32, 33].
Newer approach through the use of phytochemicals, the naturally occurring, plant-based
substances is of the current research interest in the hope to combat pancreatic cancer. Garcinol, a
bioactive agent from plant is one of the phytochemicals that has drawn researchers’ attention for
its anticancer properties, both as therapeutics and chemoprevention.
1.3 Garcinol
Garcinol is a yellow crystalline polyisoprenylated benzophenone derivative, extracted
from Garcinia indica fruit rind. Also popularly known as Kokum or Mangosteen, it can be
largely found in tropical regions of Asia and Africa. Characterized by its sweet and sour taste,
this fruit has long been incorporated in cooking, enjoyed as snack and served as a refreshing
drink. It is also traditionally used in the treatment of some illnesses such as heat strokes and
infections [34].
The chemical structure of Garcinol (C38H50O6; molecular weight 602), also called
Camboginol (Figure 1) was defined using NMR and IR spectroscopy back in 1980 by Rao and
coworkers [35]. It shares a structure similar with curcumin, a compound known to possess

9

antioxidant, antiaging and anticarcinogenic properties by means of containing both phenolic
hydroxyl groups and the ß-diketone moiety [35]. Some other known properties of garcinol
include antiulcer, antitumorigenic, antiobesity, anti-inflammatory, antibacterial and antiviral
which associated with its isomer isogarcinol [36].
1.3.1 Anticancer Properties of Garcinol
The potential of garcinol as chemopreventative and therapeutic agent for different types
of cancer have been reported by a number of studies conducted recently. The mechanistic targets
of the anticancer activity of Garcinol is depicted as Figure 2 [37].

Fig. 1 Chemical structure of garcinol [38]

Its effect on oxidative and inflammatory pathways has been investigated both in vitro and
in vivo. A colon cancer study on F344 rats conducted in Tanaka lab showed a significant
reduction in a dose-dependent manner on the formation of colon cancer precursors known as
azoxymethane-(AOM)-induced colonic aberrant crypt foci (ACF) following of 0.01% and 0.05%
dietary garcinol intervention. Garcinol has also been noted to inhibit O2-, iNOS, Nitric Oxide
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(NO) and COX2 and interestingly found to act more potently than the green tea polyphenol,
epigallocatechin gallate (EGCG) in the cell lines studied [38]. In another in vivo study, ingestion
of dietary garcinol by rats exposed with 4-nitroquinoline 1-oxide (4-NQO) to induce tongue
lesions has also shown to lower the expression of COX2 as compared to control diet [39].
Similar effect of inflammatory response was also observed in macrophage cell lines, by which
the expression of both NF-ĸB and COX2 have been down-regulated following garcinol treatment
[40].

Fig. 2 Mechanistic targets of garcinol anticancer activity [37]

Apart from that, garcinol has also been documented as being potent in halting cancerous
growth by targeting apoptosis, programmed cell death of cancer cells. In a human leukemia cell
study by Pan and coworkers, garcinol induced apoptosis at a greater rate than curcumin through
activation of cascape-3 mediated by release of cytochrome c into the cytoplasm of the cell from
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mitochondria. The increase in apoptosis was also accompanied with down-regulation of an antiapoptotic protein BCL2 together with significant up-regulation of two pro-apoptotic proteins,
Bad and Bax [41]. In another cancer cell study, garcinol also exhibited a higher potency of
growth inhibition against the colon cancer cells as compared to normal immortalized intestinal
cell line with an increase in cascape-3 activity, indicative of apoptotic pathway activation [42].
Additionally, several in vitro studies on garcinol suggested its promising role as an
antiangiogenic and anti-metastatic agent [43-45]. Garcinol studies in pancreatic cancer cell lines
conducted in our laboratory have demonstrated down-regulation of several markers of
angiogenesis and metastasis namely MMP9, IL8, PGE2 and VEGF with garcinol treatment [45].
At the present time, garcinol has not been reported to show any toxic effects and was proven by
previously conducted study as safe to be given up to 0.05% in diet orally [38]. In the discovery
of new anticancer agents, post-treatment gene expression is one of the tools often used to screen
the potential of candidate compounds in halting cancer progression. In this study, we
investigated the effect of garcinol alone and in combination with gemcitabine for potential
therapeutic effect in pancreatic cancer mouse model.
1.4 Quantitative Real-Time PCR-Based Analysis of Gene Expression
A gene that encodes a protein is determined to be expressed in a cell or group of cells
when its transcribed messenger RNA (mRNA) or the resulting protein product is detected. Most
commonly, gene expression is being measured for comparative purposes to compare the mRNA
levels of one or several genes in cells from different sources. These comparisons include studies
on cancer versus normal cells, cells from an organ in genetically modified organism versus
normal organism and also intervention studies to test a new drug or compound.
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Gene expression can be measured by many techniques. One of the techniques is
quantitative real-time polymerase chain reaction (qPCR)

which enables the continuous

monitoring of the amplification process as it occurs and uses fluorescent reporter dyes to merge
the amplification and detection steps. The assay is based on measuring the increase in fluorescent
signal, which corresponds to the amount of DNA produced during each PCR cycle.
A single PCR reaction is characterized by the PCR cycle at which fluorescence first rises
above threshold background levels called threshold cycle (CT). Hence, higher the messenger
RNA (mRNA) concentration of a target gene, lower is the CT value. The process of qPCR
consists of three steps: (1) reverse transcriptase-based conversion of RNA to complimentary
DNA (cDNA), (2) the amplification of cDNA by PCR (through repeated cycle of denaturation,
annealing and DNA fragment synthesis), and (3) the detection and quantification of amplified
products-referred as amplicons [46].
Results from a real-time PCR experiment can be calculated either using absolute or
relative quantification. In absolute quantification using the Standard Curve Method, unknowns
are being quantitated based on a known quantity in which the concentration of quantified serially
diluted DNA sample is plotted against each dilution’s CT. The CT value of an unknown can then
be used to extrapolate a value from the standard curve. In relative quantification, the aim is to
analyze changes in gene expression in a given sample relative to another reference sample such
as an untreated control sample. This type of quantification is useful for comparing the level of
gene expression of a particular gene of interest in response to a treatment. The most common
method for relative quantitation is the 2−ΔΔCT method which compares the CT value of one target
gene to another for example, an internal control (most commonly housekeeping gene such as β-
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actin and GAPDH) in a single sample [47]. In this study, we investigated the effect of garcinol
on the gene expression of genes known to be up-regulated in pancreatic cancer.
1.5 Selected Genes of Interest in Pancreatic Cancer Progression
1.5.1 Matrix metallopeptidase-9 (MMP9)
MMP9 is a type of matrix metalloproteinases (MMPs). Also called matrixins, these are
zinc-dependent enzymes that are involved in the degradation of extracellular matrix components.
MMPs play a central role in cell proliferation, invasion and metastasis of cancer cells. MMP9
from the family is constantly up-regulated in many types of cancer including pancreatic cancer.
1.5.2 Cyclin D1 (CCND1)
CCND1 a member of the highly conserved cyclin family. Cyclins function as cyclindependent kinases subunit regulators forming a complex with CDK4 or CDK6, whose activity is
required for cell cycle G1/S transition. Overexpression of CCND1 increases proliferation by
accelerating the cell transit through the G1 phase.
1.5.3 B-cell lymphoma-2 (BCL2)
BCL2 is an anti-apoptosis protein found mainly at the cytoplasmic face of the
mitochondrial outer membrane and other membrane such as endoplasmic recticulum membrane
and the nuclear envelope. BCL2 prevents the initiation of protease cascape leading to apoptosis
by directly or indirectly blocking the release of cytochrome c from the mitochondria which
results in the delay of cell death [48]. Its high expression is found in various human tumors [49].
1.5.4 Notch1
Notch signaling is involved in the cellular developmental pathway including proliferation and
apoptosis. Notch genes encode proteins which are activated upon interaction with its family
ligands. Five ligands that have been found in mammals are Dll-1, Dll-3, Dll-4, Jagged-1 and
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Jagged-1[50]. On activation, Notch is cleaved and intracellular Notch is released and shifted into
the nucleus. The intracellular Notch associates transcriptional factors which play role in
regulating the expression of target genes. Dysfunction of intracellular Notch is associated with
tumorigenesis through prevention of cell differentiation. Notch1 is one of the four vertebrate
Notch genes that have been identified: Notch1, Notch2, Notch3 and Notch4. Notch1 has been
reported to cross-talk with another major cell growth and apoptotic pathway such as nuclear
factor ĸB (NF- ĸB ) and its high expression has been noted to inhibit apoptosis [51].
Hypothesis
Based on literature and in vitro findings in our laboratory, we hypothesized that
progression of pancreatic cancer in mouse model would lead to an increase expression of MMP9,
CCND1, BCL2 and also Notch1. Moreover treatment with dietary garcinol should cause a downregulation of the above described genes in order for it to be potentially beneficial. This was
shown to be true in earlier studies from our lab in pancreatic cancer cell lines. However, the in
vitro findings need to be validated in an in vivo animal model of pancreatic cancer before
translating the effects to a clinical level. A good animal model should be in very close
resemblance to the human condition. One of the best, well-validated and clinically relevant
models of PDAC to be used for in vivo studies is the KrasLSL.G12D/+; p53R172H/+; PdxCretg/+
or KPC transgenic mouse model.
1.6

KPC Transgenic Mouse Model of Pancreatic Cancer
The KrasLSL.G12D/+;

p53R172H/+; PdxCretg/+ or KPC transgenic mouse model is

generated by crossing mice with a conditional activated Kras allele (KrasLSL.G12D) to transgenic
strain that expresses Cre recombinase in pancreatic lineages (PdxCregt) and generating a
conditionally express mutant allele of the Li-Fraumeni human ortholog,, p53R172H. Activation of
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both the KrasLSL.G12D and the p53R172H alleles occurs in tissue progenitor cells of the developing
mouse pancreas through interbreeding with PdxCretg transgenic animals. KPC mice developed
advanced PDAC at an early age and resembled many aspects of pancreatic cancer in human. This
model developed the full range of PanIN lesion that ultimately progresses to manifest carcinoma
with hundred percent penetrance. Metastases to the liver and lungs are also observed in majority
of the KPC mice which is similar to what is commonly observed in humans. Furthermore, the
KPC model also developed associated comorbidities to the human pancreatic cancer such as
cachexia, jaundice and ascites [30, 52].
To verify our in vitro findings, we have conducted an in vivo study which aimed to
investigate the effects of garcinol in pancreatic cancer mouse model. This thesis focuses on the
change in gene expression observed due to dietary garcinol treatment. The following specific
aims were proposed to meet the hypothesis that the effect of garcinol as a therapeutic agent in
pancreatic cancer will be evident in gene expression differences of selected genes from the
garcinol treated groups compared to the non-treated group.
Specific aim I: To investigate the gene expression response of the pancreatic tissue
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR)
technique.
Specific aim II: To examine the extent of gene expression response in the distant
metastasis site following garcinol treatment of the liver tissue using quantitative real-time
polymerase chain reaction (qPCR) technique.
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Chapter 2
Methodology

2.1 Animals
Forty-two male, KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+) transgenic mice aged
between 6-8 weeks old, obtained from Van Andel Institute (Grand Rapids, MI) were used in this
study. Thirty-two of them developed pancreatic cancer by KPC mutation and ten mice with nonmutated KPC from the same litter served as control.
2.2 Housing and husbandry
All animals were housed in individual cage at Wayne State University Division of
Laboratory Animal Resources (DLAR) facility under standard conditions as approved by the
Wayne State University Animal Investigation Committee (AIC). All of them were kept in the
same room with alternating 12 hours light alternating with 12 hours darkness under normal
humidity and at room temperature. Cage bedding, diets and water were replaced weekly and their
health were monitored regularly.
2.3 Experimental protocol
Upon arrival at the facility, all animals were allowed to acclimatize for one week prior to
start of the experiment. Following acclimatization period, animals were randomly distributed
into 4 and 2 experimental groups respectively and were subjected to different diet-treatment
combination as shown in Figure 3. The KPC groups, each had similar number of animal (n=8)
included the control, isocaloric diet-non treated group (KC), Garcinol diet-non treated group
(KGr), isocaloric diet-gemcitabine treated group (KGm) and garcinol diet-gemcitabine treated
group (KGG). The non-KPC groups received no chemotherapy drug treatment, also had equal
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number of animal in each group (n=5) with one group was fed with isocaloric diet (CC) and the
other was fed with garcinol diet (CGr).
2.4 Experimental diets
Three groups (KGr, KGG,CGr) were given special diet containing 0.05% Garcinol while
3 other groups (KC,KGm,CC) received standard purified diet that is isocaloric to the Garcinol
diet. Garcinol for this study was purchased from Enzo Life Sciences (Plymouth Meeting, PA).
Both the garcinol diet and the standard diet were formulated and produced by Dyets Inc.
(Bethlehem, PA). Composition of both diets is shown in Table 1.
2.5 Experimental procedures
Experimental procedures carried out for this study as summarized in Table 2 are based on
the overall project to explore the anti-cancer effects of Garcinol in pancreatic cancer mouse
model. My report will describe only a portion of the main study, investigating gene expression.
All mice were provided with their respective diets for 6 weeks and had free access to
water. Body weight, diet and water intake were recorded twice weekly throughout the study
duration. Chemotherapy injections from 100mg/5ml Gemcitabine stock were delivered to KGm
and KGG groups (5ul/g body weight) once-weekly (Week 1-5) while groups with no
chemotherapy treatment were given placebo injections of saline (0.85% NaCl). Urine was
collected once a week on weeks 2, 4 and 6 for urinary metabolomic profiling. To confirm the
presence of pancreatic cancer and for tumor progression monitoring purpose, ultrasound was
done on week 3 and 6, while MRI was done in week 1 and 5. Upon completion of the experiment
at Week 6, each animal was anesthetized with the combination of 80 mg/ml Ketamine and
20mg/ml Xylazine (5ul/g body weight) and euthanized by exsanguination and major organs
removal prior to blood and tissue collection. Pancreatic and liver tissues were flash-frozen in
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liquid nitrogen then stored at -80ºC until ready to be used for gene expression analysis (by qPCR
and miRNA microarray) and histological analysis.
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Control KPC group (KC)
Standard diet/Saline
n=8

Garcinol group (KGr)
Garcinol diet/Saline

Experimental group

n=8

KPC mice
(KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ )

n=32

Gemcitabine group (KGm)
Standard diet/Gemcitabine
n=8

KPC Garcinol Study

Gemcitabine Garcinol group
(KGG)

n=42

Garcinol diet/Gemcitabine

n=8

Control group (CC)
Control group

Standard diet/Saline
n=5

Control mice
(Littermates without mutation)
n=10

Control Garcinol group (CG)
Garcinol diet/Saline
n=5

Fig. 3 Study design

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
Control groups
CC: Control mouse, standard purified diet.
CGr: Control mouse, 0.05% garcinol diet.
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0.05% Garcinol added Diet
Ingredient kcal/g grams/
kcal/kg
kg
Casein
3.58
200
716

Regular Isocaloric Diet
Ingredient kcal/g grams/
kg
Casein, High
3.58
200
Nitrogen

L-Cystein
Sucrose
Cornstarch
Dyetrose
Soybean Oil
t-Butyl
hydroquinone
Cellulose
Mineral Mix
#210025
Vitamin Mix
#310025
Choline
Bitartrate
Garcinol

L-Cystein
Sucrose
Cornstarch
Dyetrose
Soybean Oil
t-Butyl
hydroquinone
Cellulose
Mineral Mix
#210025
Vitamin Mix
#310025
Choline
Bitartrate

4
4
3.6
3.8
9
0

3
100
396.986
132
70
0.014

12
400
1429.1496
501.6
630
0

0
0.88

50
35

0
30.8

3.87

10

38.7

0

2.5

0

0

0.5
1000.00

0
3758.2496

kcal/kg
716

4
4
3.6
3.8
9
0

3
100
397.486
132
70
0.014

12
400
1430.9496
501.6
630
0

0
0.88

50
35

0
30.8

3.87

10

38.7

0

2.5

0

1000.00

3760.0496

Table 1: Experimental Diets Composition
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Procedures
Body weight, diet intake, water intake
Gemcitabine/saline injection
MRI
Ultrasound
Urine collection
Blood and tissue collection

Frequency of Measurement
Twice weekly (Week 1-6)
Once weekly (Week 1-5)
Week 1, 5
Week 3, 6
Once weekly (Week 2,4,6)
End of study (Week 6)

Table 2: Study timeline based on the overall study

2.6 RNA Extraction
Four pancreatic samples and five liver samples from each group were taken as
representative in the gene expression analysis. Total RNA extraction was performed with a
commercial kit (RNeasy Mini Kit, Qiagen Valencia, CA, USA) according to the manufacturer’s
instructions. First, an approximate weight of 30mg of frozen liver and pancreatic tissues were
excised and placed into 700 uL QIAzol Lysis Reagent in a suitable vessel for disruption and
homogenization using tissue homogenizer until sample was uniformly homogenous. Tube
containing homogenate was then placed at room temperature (15-25˚C) for 5 minutes. 140 uL of
chloroform was then added and tube was capped securely followed by vigorous shaking for 15
seconds. The tube was then placed at room temperature for 3 minutes prior to centrifugation for
15 minutes at 12,000 rcf at 4˚C. Following centrifugation, the upper aqueous phase was
transferred to a new collection tube. 525 uL of 100% ethanol was added and mixed thoroughly
by pipetting. Next, 700 uL of sample including any precipitate was pipetted into RNeasy Mini
spin column in 2 ml collection tube and centrifuged at 10,000 rpm for 15 seconds. The flowthrough was discarded and the same step was repeated for the remainder of sample. 700 uL of
Buffer RWT was then added to RNeasy Mini spin column, centrifuged at 10,000 rpm for 15
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seconds and flow-through was discarded. 500 uL of Buffer RPE was then pipetted onto RNeasy
Mini spin column and again and centrifuged at 10,000 rpm for 15 seconds. The flow-through
was discarded and another 500 uL of Buffer RPE was added to RNeasy Mini column,
centrifuged at 10,000 rpm for 2 minutes. RNeasy Mini spin column was then places into a new
2 ml collection tube and centrifuged at full speed for 1 minute. The old collection tube was
discarded with the flow through. Finally, the RNeasy Mini spin column was transferred to a
new 1.5 ml collection tube, 40uL of RNase-free water was pipetted directly on the RNeasy Mini
spin column membrane and centrifuged for 1 minute at 10,000 rpm to elute the RNA. Quantity
measurement and spectrophotometric quality assessment (A260/280 and A260/230 ratios) of RNA
were then carried out using the Nanodrop spectrophotometer.
2.7 cDNA Preparation
Reverse transcription for liver RNA was performed using High Capacity RNA to cDNA
Master Mix kit (Applied Biosystems, Carlsbad, CA). 20 uL of RT buffer mix, 2 uL of RT
enzyme mix, 8 uL of RNA sample (equal concentrations of 1000 ng/ul for all samples) and 10
uL of nuclease-free water were mixed into 0.2 mL PCR tube and centrifuged for few seconds.
Prepared samples were then

loaded into Eppendorf mastercycler realplex 4 (Eppendorf,

Hauppauge, NY) for reverse transcription process with the following temperature setting; 25˚C
for 5 minutes, 42˚C for 30 minutes, 85˚C for 5 minutes and kept at 4˚C until retrieve for
immediate use for qRT-PCR analysis or transferred to a -20˚C freezer.
Reverse transcription for pancreatic RNA was performed using miScript II RT Kit
(Qiagen GmbH, Hilden, Germany). The reverse transcription master mix consisted of 4 uL 5x
miScript HiFlex Buffer, 2 uL miScript Nucleics Mix, 2 uL miScript Reverse Transcriptase Mix
and 4 uL RNase-free water prepared in 0.2 mL PCR tube, gently mixed and stored on ice. Next,
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8 uL template RNA (equal concentrations of 1000 ng/ul for all samples) was added to each tube
containing reverse transcription master mix, gently mixed and briefly centrifuged. All prepared
tubes were then loaded into Eppendorf mastercycler realplex 4 (Eppendorf, Hauppauge, NY) for
reverse transcription process, incubated at the following temperatures; 37˚C for 60 minutes, 95˚C
for 5 minutes and kept at 4˚C until retrieve for immediate use for qRT-PCR analysis or
transferred to a -20˚C freezer.
2.8 Quantitative Real-Time Polymerase Chain Reaction (qPCR)
qPCR was performed as part of gene expression analysis. Four genes which involved in
tumor progression were tested in pancreatic samples (CyclinD1, MMP9, BCL2, Notch1) and
three genes were tested in liver samples (CyclinD1, MMP9, BCL2) . The primer sequence of
these genes are listed in Table 3. The final reaction volume of 25 uL consisted of 12.5 uL
SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), 1 uL of 20 uM reverse
and forward primer mixture,

9.5 uL nuclease-free water and 2 uL of cDNA (equal

concentrations of 10ng/ul for all samples). qRT-PCR was carried out on the Eppendorf
mastercycler realplex 4 instrument (Eppendorf, Hauppauge, NY) in Mx3000P 96-Well Plates
(Agilent Technologies) with the following program; initial denaturing: 95˚C for 10 minutes, 45
repeats of denaturing: 95˚C (15 seconds) and elongation: 60˚C (1 minute), dissociation curve:
95˚C for 1 minute, 60˚C for 30 seconds followed by gradual temperature increase from 60˚C
to 95˚C in 20 minutes and finally at 95˚C for 30 seconds. Each gene was analyzed in triplicate
with single NTC. mRNA expression levels in the samples were calculated relative to control,
isocaloric diet-no chemotherapy group (KC) using the comparative CT method: ∆∆CT = ∆CT
sample

- ∆CT control, fold change = 2-∆∆CT. β-actin was used to normalized the expression values

(∆CT).
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2.9 Data Analysis
A fold change cut-off of more than 2 was used in determining any significant change of
gene expression relative to control.
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Primer’s
Name

Forward Sequence

Reverse Sequence

CyclinD1

5′-CCTCCAGAGGGCTGT
CGGCGCAGTAGCAGA- 3′

5′-TCTTACCTCCAGCAT
CCAGGTGGCCACGAT-3′

MMP9

5′- GCTCCTGGTCTCCTG
GCTT-3′

5′-GTCCCACTTGAGGC
CTTTGA-3′

BCl2

5′-CCTGTGGATGACTGA
GTACC-3′
5′-CACTGTGGGCGGGT
CC-3′

5′-GAGACAGCCAGGAG
AAATCA-3′
5′-GTTGTATTGGTTCGGC
ACCAT-3′

5′-ACCAACTGGGACGA
CATGGAGAAG-3′

5′-TACGACCAGAGGCAT
ACAGGGACT-3′

Notch-1
β-Actin

Table 3: Primer sequence of the studied genes
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Chapter 3
Results

The body weight, diet intake, MRI and histological data from our overall study are
summarized in Table 4. In this study, we have confirmed the presence of pancreatic tumor in the
experimental groups by ultrasound, MRI and histology. The 0.05% dosage of garcinol added in
diet has shown to be well tolerated in this study with 100% survival rate was reported in nonpancreatic cancer group. The data of the results mentioned above will be presented elsewhere.
The data on change in gene expression due to garcinol intervention, the focus of my study is
presented here.

Data
Body weight
Diet intake
MRI
Histology

miRNA microarray

Observation
No significant difference between experimental
groups
No significant difference between all groups
Reduction in number and tumor size in garcinol
treated groups (KGr and KGG)
Significant reduction in total PanIN count in
garcinol treated groups (KGr and KGG)
Less number of PanIN-3 in garcinol treated
groups (KGr and KGG)
miRNA related to pancreatic cancer were
identified and found to be regulated in favorable
manner

Table 4: Body weight, diet intake, MRI and histological data from the overall study

Specific aim I: To investigate the gene expression response of the pancreatic tissue
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR)
technique.
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3.1 Gene Expression Analysis of Pancreatic Tissues
KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+) transgenic mouse develop tumor in the
pancreas. Data from experimental group (KC, KGr, KGm and KGG) are presented. Gene
expression levels are presented relative to the non-treated pancreatic cancer group (KC).
Cyclin D1 (CCND1)
As can be seen from Figure 4, the relative pancreatic mRNA expression of CCND1 for
all three treatments significantly decreased compared to the non-treated cancer group with
garcinol and garcinol-gemcitabine combination exhibiting more profound reduction. Garcinol
significantly reduced CCND1 expression to much lower level compared to gemcitabine.
Likewise, garcinol-gemcitabine combination also significantly lowered CCND1 expression than
gemcitabine alone.
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Relative Expression (Fold Change)

1.2
1

a

0.8
0.6
0.4

c

0.2

b

b

0
KC

KGr

KGm

KGG

Fig. 4 Relative pancreatic mRNA expression of CCND1. The expression is presented as fold
change with respect to KC. a is significantly different from b and c. b is significantly different from
c
.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Matrix metallopeptidase-9 (MMP9)
Figure 5 shows the relative pancreatic mRNA expression of MMP9. Treatment with
garcinol, gemcitabine and garcinol-gemcitabine combination significantly decreased the mRNA
level of MMP9 compared to the non-treated group. The down-regulation was most significantly
pronounced with garcinol-gemcitabine combination. Garcinol significantly reduced MMP9
expression at much lower level compared to gemcitabine and also garcinol-gemcitabine
combination too had significantly decreased MMP9 expression more compared to gemcitabine.
Moreover, this combination decreased the expression of MMP9 more than garcinol alone at a
significant level.
Notch-1
All three treatments with garcinol, gemcitabine and garcinol-gemcitabine had
significantly down-regulated Notch1 compared to the non-treated cancer group (Figure 6).
Garcinol lowered the Notch1 expression most significantly among the three. Garcinol
significantly reduced Notch1 expression at much lower level compared to gemcitabine. The
combination of garcinol-gemcitabine had significantly decreased Notch1 expression more than
gemcitabine and garcinol treatment alone.
B-cell lymphoma-2 (BCL2)
The relative pancreatic mRNA expression of BCL2 is presented in Figure 7. It can be
seen that garcinol slightly decreased the expression of BCL2. However this down-regulation was
not significant. Gemcitabine and garcinol-gemcitabine combination increased BCL2 expression
level compared to both no treatment and garcinol also at a non-significant level.
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Relative Expression (Fold Change)

1.2

a
1
0.8
0.6

c
0.4
0.2

b
b

0
KC

KGr

KGm

KGG

Fig. 5 Relative pancreatic mRNA expression of MMP9. The expression is presented as fold
change with respect to KC. a is significantly different from b and c. b is significantly different
from c.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Relative Expression (Fold Change)

1.2
1

a

0.8
0.6

c

0.4
0.2

b

b
0
KC

KGr

KGm

KGG

Fig. 6 Relative pancreatic mRNA expression of NOTCH1. The expression is presented as fold
change with respect to KC. a is significantly different from b and c. b is significantly different
from c.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Relative Expression (Fold Change)

1.4
1.2
1
0.8
0.6
0.4
0.2

0
KC

KGr

KGm

KGG

Fig. 7 Relative pancreatic mRNA expression of BCL2. The expression is presented as fold
change with respect to KC. There is no significant difference in mRNA expression levels of each
group in comparison with KC.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Specific aim II: To examine the extent of gene expression response in the distant
metastasis site following garcinol treatment of the liver tissue using quantitative real-time
polymerase chain reaction (qPCR) technique.
3.2 Gene Expression Analysis of Liver Tissues
Liver is one of the first organs for the primary tumor in the pancreas to be metastasized.
Data from experimental group (KC, KGr, KGm, KGG) is presented. Gene expression levels are
presented relative to the non-treated pancreatic cancer group (KC).
Cyclin D1 (CCND1)
Figure 8 shows the relative liver mRNA expression of CCND1. In the experimental
groups, the expression of CCND1 was significantly decreased with garcinol treatmeant,
gemcitabine treatment and garcinol-gemcitabine treatment combination with the later (garcinolgemcitabine) showing the most down-regulation of CCND1 expression compared to no
treatment. It can be seen that garcinol-gemcitabine combination decreased CCND1 expression
more than garcinol and gemcitabine treatment alone but the decrease in expression was not
significant, as compared to either treatment alone.
Matrix metallopeptidase-9 (MMP9)
As shown in Figure 9, the relative liver mRNA expression of MMP9 in the experimental
groups was significantly decreased with garcinol treatmeant, and garcinol-gemcitabine treatment
combination. However, down-regulation of MMP9 following Gemcitabine treatment was at a
non-significant level. Garcinol and garcinol-gemcitabine combination decreased the MMP9
expression at a lower, non-significant levels compared to gemcitabine.
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Relative Expression (Fold Change)
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Fig. 8 Relative liver mRNA expression of CCND1. The expression is presented as fold change
with respect to KC. a is significantly different from b.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Relative Expression (Fold Change)
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Fig. 9 Relative liver mRNA expression of MMP9. The expression is presented as fold change
with respect to KC. a is significantly different from b. There is no significant difference in mRNA
expression levels of KGm in comparison with KC, KGr and KGG.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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B-cell lymphoma-2 (BCL2)
It can be seen from Figure 10 that both gemcitabine and garcinol-gemcitabine
combination treatment of the experimental group significantly decreased the expression of BCL2
with the combined treatment being more pronounced. Garcinol also exhibited a reduction in
BCL2 level but the decrease was not significant.
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Relative Expression (Fold Change)
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Fig. 10 Relative liver mRNA expression of BCL2. The expression is presented as fold change
with respect to KC. a is significantly different from b. There is no significant difference in mRNA
expression level of KGr in comparison with KC.

Experimental groups
KC: Pancreatic cancer mouse, standard purified diet + no drug treatment.
KGr: Pancreatic cancer mouse, 0.05% garcinol diet + no drug treatment.
KGm: Pancreatic cancer mouse, standard purified diet + gemcitabine drug treatment.
KGG: Pancreatic cancer mouse, 0.05% garcinol diet + gemcitabine drug treatment.
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Chapter 4
Discussion

Pancreatic cancer is currently ranked as the fourth leading cause of cancer-related deaths
in The United States with high mortality rate majorly contributed by late diagnosis, early
metastasis of tumors and poor response to treatments, making it so important to develop new
approaches in order to improve the prognosis of this lethal disease. Most chemotherapeutic
treatments for pancreatic cancer are at a disadvantage of having adverse toxic reactions. Thus,
development of effective preventative and/or therapeutic treatments for pancreatic cancer that are
relatively nontoxic from single agents or combination with an established drug treatment is
warranted. This thesis reports the potential anticancer effect of garcinol, a compound extracted
from Garcinia indica fruit rind which may have promise for treating this lethal malignancy.
Using KPC mouse-model for pancreatic cancer, this study has evaluated the mRNA expression
response of selected genes in pancreatic tumorigenesis following garcinol treatment alone,
gemcitabine treatment alone and also garcinol-gemcitabine combination relative to non-treated
group using quantitative real-time polymerase chain reaction (qPCR) technique.
In this study, we report the potential of garcinol for its future use as a chemotherapeutic
agent for pancreatic cancer. Figure 11 summarizes the in vivo anticancer activity of garcinol in
pancreatic cancer as observed from this study. We report herein that garcinol caused a significant
down-regulation of three out of four genes tested which could possibly halt the tumor
progression via inhibition of proliferation, angiogenesis and metastasis and via increment in
apoptosis activity. Interestingly, this study also report the similar observation with garcinolgemcitabine treatment combination. These results show that garcinol may have potential in
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pancreatic cancer chemoprevention not only limited by its use as a single treatment agent but
may provide additive effect when use in combination with gemcitabine.

↓ Notch1
Proapoptotic
Anti-proliferative

↓ MMP9
Anti-angiogenesis
Anti-metastasis
Garcinol &
Garcinol + gemcitabine

↓ CCND1
Anti-proliferative

Fig. 11 In vivo anticancer activity of Garcinol in pancreatic cancer

The cyclin D1 (CCND1) is frequently over expressed in pancreatic ductal
adenocarcinoma. Cyclins function as cyclin-dependent kinases subunit regulators forming a
complex with CDK4 or CDK6, whose activity is required for cell cycle G1/S transition.
Overexpression of CCND1 increases proliferation by accelerating the cell transit through the G1
phase. Moreover, there is also present evidence that CCND1 plays a role in tumor cell migration
[53]. In this study, we observed that both garcinol and garcinol-gemcitabine treatment
significantly reduced the expression of CCND1 thus, suggesting the anti-proliferative property of
garcinol by its ability to arrest cell cycle.
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Matrix metalloproteinases (MMPs) also called matrixins are zinc-dependent enzymes
known to be the agent to degrade extracellular matrix components. Its role in tumor metastasis,
invasion, angiogenesis and metastasis is well established. This current study demonstrates that
garcinol down-regulated the level of pancreatic MMP9 relative to untreated group significantly.
Moreover, it was also observed that garcinol and gemcitabine displayed synergistic effect in
inhibiting MMP9 when compared to single treatment of garcinol or gemcitabine. Similar
observation was obtained for liver samples. This finding accords the earlier in vitro observation
which showed that garcinol causes inhibition of MMP9 activity [45]. These results provide
further support for the hypothesis that garcinol is capable of arresting metastasis and cell
invasion by interrupting MMP9 activity.
Apoptosis induction is one of the most important aspects in evaluating anticancer
properties of treated animals. BCL2 is as an anti-apoptotic protein known to be overexpressed in
pancreatic cancer [49] and prevents the initiation of protease caspase leading to apoptosis by
directly or indirectly blocking the release of cytochrome c from the mitochondria which results
in the delay of cell death [48]. It was observed from this study that garcinol slightly downregulated the expression of BCL2 in both pancreatic and liver samples at a non-significant level.
Contrary to expectations, garcinol-gemcitabine combination increased pancreatic BCL2
expression compared to both no treatment and garcinol also at a non-significant level. The
opposite observation was obtained in liver samples in which combination of garcinolgemcitabine treatment showed an additive effect resulted in a significant reduction of BCL2
expression. It is well accepted that p53 mutation leads to activation of BCL2 in pancreatic
cancer. Thus, we speculate that this difference in observation is due to the animal model used in
this research. The KPC mouse model selected for this study has conditional mutations in K-ras
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and p53 genes.The activation of the mutant p53 in this model occurs exclusively in tissue
progenitor cells of the developing mouse pancreas which leads to the activation of BCL2 in the
pancreas. This high activation of BCL2 in the pancreas might provide the possible explanation
on why was the significant down-regulation of BCL2 with garcinol-gemcitabine treatment
observed only in liver sample but not in pancreatic sample.
The Notch signaling pathway is a fundamental signaling system used by neighboring
cells to communicate with each other in order to assume their proper developmental role. Notch
signaling is involved in the cellular developmental pathway including proliferation and
apoptosis. Notch1 has been reported to cross-talk with another major cell growth and apoptotic
pathway such as nuclear factor ĸB (NF- ĸB ) and its high expression has been noted to inhibit
apoptosis [51]. It has also been reported in the study by Wang et al., that down-regulation of
Notch1 inhibited cell growth and induced apoptosis in pancreatic cancer cells [51]. However,
very little was found in the literature on the question of whether garcinol is capable of downregulating Notch1 in pancreatic cancer. Our observations highlight the therapeutic benefit of
garcinol by a significant down-regulation of Notch1 level compared to the non-treated group. It
was observed that the combination of garcinol-gemcitabine effectively down-regulated Notch1
more than gemcitabine and garcinol treatment alone. From these earlier findings it is likely that
the potential inhibition of cell growth and apoptosis induction by garcinol treatment in pancreatic
cancer is achieved through down-regulation of Notch1.
Moreover, the findings on garcinol and its synergistic effect with gemcitabine in the
down-regulation of several genes as discussed above are also supported by the data from other
experiments conducted in our overall study, which will be reported elsewhere. Our MRI data
showed that garcinol had effectively reduced the number and size of tumor and a greater effect
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was observed in the garcinol-gemcitabine treated group. From our histological observation, we
found that garcinol alone and garcinol-gemcitabine combination significantly reduced the
number of all PanINs (PanIN-1, PanIN-2 and PanIN-3). It was also observed that PanIN-3 lesion
count in garcinol treated groups (KGr and KGG) was lowered compared to the untreated group.
These histological findings are indicative of garcinol’s potential in prolonging the onset of
adenocarcinoma and in halting its progression.
In conclusion, despite the need for further investigation, garcinol exhibits antipoliferative, proapoptotic, anti-angiogenesis and anti-metastatic properties which is evident by
the significant down-regulation of CCND1, MMP9 and Notch1. The findings in this study add to
a growing body of literature on anticancer effects of garcinol and contributes to additional
evidence that suggests its chemotherapeutic effect on pancreatic cancer previously shown in in
vitro setting is extended into animal model. Interestingly, we also showed that the promising
pancreatic cancer chemotherapeutic effect of garcinol is not only limited by its use as a single
treatment agent. Garcinol may also provide additive effect when use in combination with
gemcitabine suggesting its potential use as a natural adjuvant in pancreatic cancer treatment
regimens. Further investigation and experimentation on garcinol’s anticancer effect in pancreatic
cancer animal models investigating many other mechanistic targets is strongly recommended.
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Pancreatic cancer is currently ranked as the fourth leading cause of cancer-related deaths
in The United States making it so important to develop new approaches in order to improve the
prognosis of this lethal disease. Chemotherapy drugs as treatment for pancreatic cancer are
known to have adverse toxic reactions. Thus, development of treatments for pancreatic cancer
that are relatively nontoxic is warranted. This thesis reports the potential anticancer effect of
garcinol, a compound extracted from Garcinia indica fruit rind which may have promise for
treating this lethal malignancy. Using KPC mouse-model for pancreatic cancer, this study has
evaluated the mRNA expression response of selected genes in pancreatic tumorigenesis
following garcinol treatment using quantitative real-time polymerase chain reaction (qPCR)
technique. We concluded from this study that garcinol and its combination with gemcitabine
exhibit anti-poliferative, proapoptotic, anti-angiogenesis and anti-metastatic properties which is
evident by the significant down-regulation of CCND1, MMP9 and Notch1 in both pancreatic and
liver tissues. The findings in this study contribute to additional evidence that suggests its
chemotherapeutic effect on pancreatic cancer previously shown in in vitro setting is extended
into animal model.
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